Royal Bank of Canada’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.84M Sell
155,206
-6,452
-4% -$154K ﹤0.01% 2611
2025
Q4
$3.77M Sell
161,658
-17,939
-10% -$400K ﹤0.01% 2650
2025
Q3
$3.54M Sell
179,597
-33,625
-16% -$692K ﹤0.01% 2938
2025
Q2
$4.63M Sell
213,222
-247
-0.1% -$5.83K ﹤0.01% 2631
2025
Q1
$5.18M Buy
213,469
+60,040
+39% +$1.35M ﹤0.01% 2234
2024
Q4
$3.2M Sell
153,429
-5,583
-4% -$120K ﹤0.01% 2665
2024
Q3
$3.16M Buy
159,012
+85,654
+117% +$1.59M ﹤0.01% 2646
2024
Q2
$1.14M Buy
73,358
+7,478
+11% +$116K ﹤0.01% 3334
2024
Q1
$1.05M Sell
65,880
-23,860
-27% -$360K ﹤0.01% 3426
2023
Q4
$1.51M Buy
89,740
+12,574
+16% +$172K ﹤0.01% 3306
2023
Q3
$902K Sell
77,166
-11,968
-13% -$160K ﹤0.01% 3526
2023
Q2
$1.2M Buy
89,134
+6,724
+8% +$96.8K ﹤0.01% 3221
2023
Q1
$1.37M Sell
82,410
-5,930
-7% -$97.8K ﹤0.01% 3106
2022
Q4
$1.64M Buy
88,340
+39,864
+82% +$614K ﹤0.01% 3076
2022
Q3
$622K Buy
48,476
+6,155
+15% +$72.9K ﹤0.01% 3831
2022
Q2
$297K Sell
42,321
-5,332
-11% -$39.1K ﹤0.01% 4479
2022
Q1
$394K Sell
47,653
-12,786
-21% -$90.4K ﹤0.01% 4467
2021
Q4
$410K Buy
60,439
+9,834
+19% +$64.7K ﹤0.01% 4654
2021
Q3
$269K Sell
50,605
-98,132
-66% -$537K ﹤0.01% 4900
2021
Q2
$855K Buy
148,737
+105,246
+242% +$543K ﹤0.01% 3798
2021
Q1
$200K Buy
43,491
+1,138
+3% +$4.52K ﹤0.01% 4956
2020
Q4
$142K Sell
42,353
-40,147
-49% -$135K ﹤0.01% 5111
2020
Q3
$245K Sell
82,500
-667
-0.8% -$2.61K ﹤0.01% 4401
2020
Q2
$384K Sell
83,167
-536
-0.6% -$2.41K ﹤0.01% 3982
2020
Q1
$322K Buy
83,703
+1,203
+1% +$4.94K ﹤0.01% 3980
2019
Q4
$309K Sell
82,500
-436
-0.5% -$2.04K ﹤0.01% 4315
2019
Q3
$440K Sell
82,936
-7,440
-8% -$39.6K ﹤0.01% 3921
2019
Q2
$347K Sell
90,376
-74,624
-45% -$322K ﹤0.01% 4105
2019
Q1
$842K Sell
165,000
-6
-0% -$18 ﹤0.01% 3323
2018
Q4
$317K Sell
165,006
-2,176
-1% -$6.23K ﹤0.01% 4046
2018
Q3
$632K Buy
167,182
+1,956
+1% +$6.13K ﹤0.01% 3733
2018
Q2
$516K Buy
165,226
+136
+0.1% +$413 ﹤0.01% 3766
2018
Q1
$394K Sell
165,090
-440
-0.3% -$1.46K ﹤0.01% 3865
2017
Q4
$647K Sell
165,530
-5,957
-3% -$19.7K ﹤0.01% 3596
2017
Q3
$432K Buy
171,487
+6,446
+4% +$17.7K ﹤0.01% 3917
2017
Q2
$455K Buy
165,041
+41
+0% +$86 ﹤0.01% 3723
2017
Q1
$322K Sell
165,000
-1,013
-0.6% -$1.29K ﹤0.01% 3990
2016
Q4
$174K Sell
166,013
-70,048
-30% -$80K ﹤0.01% 4570
2016
Q3
$257K Buy
236,061
+71,031
+43% +$63.9K ﹤0.01% 4248
2016
Q2
$117K Buy
+165,030
New +$133K ﹤0.01% 4713
2015
Q4
Sell
-3,764
Closed -$11K 6657
2015
Q3
$11K Sell
3,764
-823
-18% -$3.55K ﹤0.01% 5841
2015
Q2
$19K Buy
4,587
+2,987
+187% +$11.9K ﹤0.01% 5722
2015
Q1
$7K Sell
1,600
-400
-20% -$1.44K ﹤0.01% 5654
2014
Q4
$6K Hold
2,000
﹤0.01% 5746
2014
Q3
$7K Hold
2,000
﹤0.01% 5566
2014
Q2
$5K Sell
2,000
-56
-3% -$120 ﹤0.01% 5556
2014
Q1
$5K Buy
2,056
+56
+3% +$117 ﹤0.01% 5564
2013
Q4
$4K Hold
2,000
﹤0.01% 5639
2013
Q3
$6K Hold
2,000
﹤0.01% 5572
2013
Q2
$2K Buy
+2,000
New +$1.6K ﹤0.01% 5608

Other funds holding CPRX

Royal Bank of Canada's CPRX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Catalyst Pharmaceutical (CPRX) stake by 4% in Q1 2026, selling an estimated $154K and leaving 155,206 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Royal Bank of Canada first reported a position in CPRX in Q2 2013 and has held it in 50 quarters since. The position peaked at $5.18M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Royal Bank of Canada held 155,206 shares of Catalyst Pharmaceutical worth $3.84M as of Q1 2026.
  • Royal Bank of Canada sold 6,452 Catalyst Pharmaceutical shares in Q1 2026, an estimated $154K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2611 holding.
  • Royal Bank of Canada first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 50 quarters since.
  • Royal Bank of Canada's Catalyst Pharmaceutical position peaked at $5.18M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.